Grace Therapeutics
GRCE
17 hedge funds and large institutions have $391K invested in Grace Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.5% less ownership
Funds ownership: 0.95% → 0.44% (-0.5%)
35% less funds holding
Funds holding: 26 → 17 (-9)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
79% less capital invested
Capital invested by funds: $1.88M → $391K (-$1.49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$74.5K |
| 2 |
Jane Street
New York
|
+$62.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$43.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.06K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$573K |
| 2 |
VF
Virtu Financial
New York
|
-$211K |
| 3 |
Squarepoint
New York
|
-$53K |
| 4 |
Morgan Stanley
New York
|
-$25.1K |
| 5 |
MMPW
Mitchell McLeod Pugh & Williams
Mobile,
Alabama
|
-$25K |
GRCE Hedge Fund Activity: Q3 2021 in Review
17 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2021, worth a combined $391K — down 79% from $1.88M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GRCE and 4 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $74.5K. The largest seller was Renaissance Technologies, cutting an estimated $573K.
- 17 institutional investors held Grace Therapeutics (GRCE) as of Q3 2021, down from 26 in Q2 2021.
- Funds reported $391K of Grace Therapeutics stock for Q3 2021, down 79% quarter-over-quarter.
- 4 funds opened new Grace Therapeutics positions in Q3 2021 and 12 closed out, a net change of -8 holders.
- The largest Grace Therapeutics buyer in Q3 2021 was Citadel Advisors, an estimated $74.5K added.
- The largest Grace Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $573K sold.
Based on aggregated 13F filings for Q3 2021.